Decreased beta-adrenergic responsiveness following hypertrophy occurs only in cardiomyocytes that also re-express beta-myosin heavy chain

European Journal of Heart Failure

Volumn 11, Issue 7, 2009, Pages 648-652

  Pandya, Kumar ^a   Porter, Kristine ^b   Rockman, Howard A ^b   Smithies, Oliver ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Beta adrenergic receptors; Beta myosin heavy chain; Cardiac hypertrophy

Indexed keywords

BETA ADRENERGIC RECEPTOR; ISOPRENALINE; MYOSIN HEAVY CHAIN BETA; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; MYOSIN HEAVY CHAIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA CONSTRICTION; ARTICLE; CONTROLLED STUDY; ECHOCARDIOGRAPHY; GENE EXPRESSION; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART MUSCLE CELL; HEART VENTRICLE HYPERTROPHY; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; ANIMAL; BIOSYNTHESIS; CARDIOMEGALY; CARDIOMYOPATHY; CYTOLOGY; DISEASE MODEL; DRUG EFFECTS; ECHOGRAPHY; HEART CONTRACTION; HEART MUSCLE; METABOLISM; PATHOPHYSIOLOGY;

ADRENERGIC BETA-AGONISTS; ANIMALS; CARDIOMEGALY; CARDIOMYOPATHIES; DISEASE MODELS, ANIMAL; ISOPROTERENOL; MICE; MYOCARDIAL CONTRACTION; MYOCARDIUM; MYOSIN HEAVY CHAINS; RECEPTORS, ADRENERGIC, BETA;

EID: 67650095181     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1093/eurjhf/hfp073     Document Type: Article

References (33)

1. Sadoshima J, Izumo S. The cellular and molecular response of cardiac myocytes to mechanical stress. Annu Rev Physiol 1997; 59:551 -571.
2. Weiss A, Leinwand LA. The mammalian myosin heavy chain gene family. Annu Rev Cell Dev Biol 1996; 12:417-439.
3. Abraham WT, Gilbert EM, Lowes BD, Minobe WA, Larrabee P, Roden RL, Dutcher D, Sederberg J, Lindenfeld JA, Wolfel EE, Shakar SF, Ferguson D, Volkman K, Linseman JV, Quaife RA, Robertson AD, Bristow MR. Coordinate changes in Myosin heavychain isoform gene expression are selectivelyassociated with alterations in dilated cardiomyopathy phenotype. Mol Med 2002; 8:750-760.
4. Schiaffino S, Samuel JL, Sassoon D, Lompre AM, Garner I, Marotte F, Buckingham M, Rappaport L, Schwartz K. Nonsynchronous accumulation of alpha-skeletal actin and beta-myosin heavy chain mRNAs during early stages of pressure-overload-induced cardiac hypertrophy demonstrated by in situ hybridization. Circ Res 1989; 64:937-948.
5. Schwartz K, Carrier L, Chassagne C, Wisnewsky C, Boheler KR. Regulation of myosin heavy chain and actin isogenes during cardiac growth and hypertrophy. Symp Soc Exp Biol 1992; 46:265-272.
6. Blaxall BC, Spang R, Rockman HA, Koch WJ. Differential myocardial gene expression in the development and rescue of murine heart failure. Physiol Genomics 2003; 15:105-114.
7. Krenz M, Sanbe A, Bouyer-Dalloz F, GulickJ, Klevitsky R, Hewett TE, Osinska HE, Lorenz JN, Brosseau C, Federico A, Alpert NR, Warshaw DM, Perryman MB, Helmke SM, Robbins J. Analysis of myosin heavy chain functionality in the heart. J Biol Chem 2003; 278:17466-17474.
8. Krenz M, Robbins J. Impact of beta-myosin heavy chain expression on cardiac function during stress. J Am Coll Cardiol 2004; 44:2390-2397.
9. Tardiff JC, Hewett TE, Factor SM, Vikstrom KL, Robbins J, Leinwand LA. Expression of the beta (slow)-isoform of MHC in the adult mouse heart causes dominant-negative functional effects. Am J Physiol Heart Circ Physiol 2000; 278:H412-H419.
10. Bristow MR. Beta-adrenergic receptor blockade in chronic heart failure. Circulation 2000; 101:558-569.
11. Port JD, Bristow MR. Altered beta-adrenergic receptor gene regulation and signaling in chronic heart failure. J Mol Cell Cardiol 2001; 33:887-905.
12. Rockman HA, Koch WJ, Lefkowitz RJ. Seven-transmembrane-spanning receptors and heart function. Nature 2002; 415:206-212.
13. Tilley DG, Rockman HA. Role of beta-adrenergic receptor signaling and desensi- tization in heart failure: new concepts and prospects for treatment. Expert Rev Cardiovasc Ther 2006; 4:417-432.
14. Bohm M, Flesch M, Schnabel P. Role of G-proteins in altered beta-adrenergic responsiveness in the failing and hypertrophied myocardium. Basic Res Cardiol 1996; 91(Suppl. 2):47-51.
15. Bohm M, Lohse MJ. Quantification of beta-adrenoceptors and beta-adrenoceptor kinase on protein and mRNA levels in heart failure. Eur Heart J1994; 15(Suppl. D):30-34.
16. Brodde OE. Beta-adrenoceptor blocker treatment and the cardiac beta- adrenoceptor-G-protein(s)-adenylyl cyclase system in chronic heart failure. Naunyn Schmiedebergs Arch Pharmacol 2007; 374:361 -372.
17. Harding SE, Brown LA, Wynne DG, Davies CH, Poole-Wilson PA. Mechanisms of beta adrenoceptor desensitisation in the failing human heart. Cardiovasc Res 1994;28:1451 -1460.
18. Lohse MJ, Engelhardt S, Eschenhagen T. What is the role of beta-adrenergic signaling in heart failure? Circ Res 2003; 93:896-906.
19. Cleland JG, Bristow MR, Erdmann E, Remme WJ, Swedberg K, Waagstein F. Beta- blocking agents in heart failure. Should they be used and how? Eur Heart J1996;17:1629-1639.
20. Hjalmarson A, Kneider M, Waagstein F. The role of beta-blockers in left ventricular dysfunction and heart failure. Drugs 1997; 54:501 -510.
21. Kaumann AJ, Molenaar P. The low-affinity site of the beta1-adrenoceptor and its relevance to cardiovascular pharmacology. Pharmacol Ther 2008; 118:303 -336.
22. Tachibana H, Naga Prasad SV, Lefkowitz RJ, Koch WJ, Rockman HA. Level of beta-adrenergic receptor kinase 1 inhibition determines degree of cardiac dys function after chronic pressure overload-induced heart failure. Circulation 2005;111:591 -597.
23. Waagstein F. Efficacy of beta blockers in idiopathic dilated cardiomyopathy and ischemic cardiomyopathy. Am JCardiol 1997; 80:45J-49J.
24. Pandya K, Kim HS, Smithies O. Fibrosis, not cell size, delineates (beta)-myosin heavy chain reexpression during cardiac hypertrophy and normal aging in vivo. Proc Natl Acad Sci USA 2006; 103:16864-16869.
25. Perrino C, Naga Prasad SV, Mao L, Noma T, Yan Z, Kim HS, Smithies O, Rockman HA. Intermittent pressure overload triggers hypertrophy-independent cardiac dysfunction and vascular rarefaction. JClin Invest 2006; 116:1547-1560.
26. Pandya K, Cowhig J, Brackhan J, Kim HS, Hagaman J, Rojas M, Carter CW Jr, Mao L, Rockman HA, Maeda N, Smithies O. Discordant on/off switching of gene expression in myocytes during cardiac hypertrophy in vivo. Proc Natl Acad Sci USA 2008; 105:13063-13068.
27. Lowes BD, Gilbert EM, Abraham WT, Minobe WA, Larrabee P, Ferguson D, Wolfel EE, Lindenfeld J, Tsvetkova T, Robertson AD, Quaife RA, Bristow MR. Myocardial gene expression in dilated cardiomyopathy treated with beta-blocking agents. N Engl JMed 2002; 346:1357-1365.
28. Yasumura Y, Takemura K, Sakamoto A, Kitakaze M, Miyatake K. Changes in myocardial gene expression associated with beta-blocker therapy in patients with chronic heart failure. JCard Fail 2003; 9:469-474.
29. Sucharov CC, Mariner PD, Nunley KR, Long C, Leinwand L, Bristow MR. A beta1-adrenergic receptor CaM kinase II-dependent pathway mediates cardiac myocyte fetal gene induction. Am J Physiol Heart Circ Physiol 2006; 291:H1299-H1308.
30. Brodde OE. Beta-adrenergic receptors in failing human myocardium. Basic Res Cardiol 1996; 91(Suppl. 2):35-40.
31. Hajjar RJ, Muller FU, Schmitz W, Schnabel P, Bohm M. Molecular aspects of adre- nergic signal transduction in cardiac failure. JMol Med 1998; 76:747-755.
32. Bristow MR, Ginsburg R, Minobe W, Cubicciotti RS, Sageman WS, Lurie K,Billingham ME, Harrison DC, Stinson EB. Decreased catecholamine sensitivity and beta-adrenergic-receptor density in failing human hearts. N Engl J Med 1982; 307:205-211.
33. Bristow MR, Minobe W, Rasmussen R, Larrabee P, Skerl L, Klein JW,Anderson FL, Murray J, Mestroni L, Karwande SV. Beta-adrenergic neuroeffector abnormalities in the failing human heart are produced by local rather than systemic mechanisms. JClin Invest 1992; 89:803 -815.